Find, compare & contact
Gallopamil
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Gallopamil API 16662-47-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Gallopamil. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Gallopamil
- Synonyms:
- Cas Number:
- 16662-47-8
- DrugBank number:
- DB12923
- Unique Ingredient Identifier:
- 39WPC8JHR8
General Description:
Gallopamil, identified by CAS number 16662-47-8, is a notable compound with significant therapeutic applications. Gallopamil has been used in trials studying the treatment of Asthma.
Classification:
Gallopamil belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine, classified under the direct parent group Phenylbutylamines. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Phenylbutylamines subclass.
Categories:
Gallopamil is categorized under the following therapeutic classes: Agents causing hyperkalemia, Amines, Antiarrhythmic agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Ethylamines, Membrane Transport Modulators, P-glycoprotein inhibitors, Phenethylamines, Phenylalkylamine Derivatives, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Selective Calcium Channel Blockers With Direct Cardiac Effects, Vasodilating Agents, Verapamil and analogues. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Gallopamil is a type of Other calcium Channel Blockers
Other calcium channel blockers are a category of pharmaceutical active pharmaceutical ingredients (APIs) that work by inhibiting the influx of calcium ions into cells through voltage-gated calcium channels. These medications are primarily used to treat various cardiovascular conditions, such as hypertension (high blood pressure) and angina (chest pain).
Unlike commonly known calcium channel blockers like dihydropyridines and non-dihydropyridines, other calcium channel blockers encompass a diverse group of drugs that possess calcium channel-blocking activity but may have different chemical structures and mechanisms of action.
These APIs exert their therapeutic effects by binding to specific calcium channels in cardiac and smooth muscle cells, reducing calcium entry and subsequent muscle contraction. By doing so, they relax blood vessels, improve blood flow, and reduce cardiac workload, resulting in lower blood pressure and alleviation of angina symptoms.
Some examples of other calcium channel blockers include bepridil, mibefradil, and verapamil. These drugs may have additional effects beyond calcium channel blockade, such as antiarrhythmic properties or interactions with other receptor systems.
As with any medication, other calcium channel blockers may have potential side effects, including dizziness, flushing, constipation, and peripheral edema. Therefore, it is important to use these drugs under the supervision of a healthcare professional and follow the prescribed dosage instructions.
In conclusion, other calcium channel blockers are a diverse class of pharmaceutical APIs that act by blocking calcium channels, leading to decreased blood pressure and relief from angina. These medications offer an alternative treatment option for cardiovascular conditions and should be used as directed by a healthcare provider to ensure safety and efficacy.
